Vapreotide in Treating Patients Undergoing Elective Pancreatic Resection

Summary

RATIONALE: Drugs such as vapreotide may prevent complications following pancreatic resection. It is not yet known if vapreotide is more effective than no further therapy in preventing side effects of pancreatic resection. PURPOSE: This randomized phase III trial is studying vapreotide to see how well it works compared to a placebo in preventing complications in patients undergoing surgery for pancreatic cancer.

Timeline

Start

2001-03

Primary completion

2001-03

Completion

2002-04

Outcome

Outcome not reported

Stopped: “Teminated by the DSMB because there are no differences between the control group and the Vapreotide group”

Drugs

Indications